Loading…
TuHURA Biosciences, Inc., a clinical stage immuno-oncology company, that develops novel technologies for the treatment of cancer immunotherapies. The company's lead product candidate includes IFx2.0, an innate immune agonist designed to overcome primary resistance to checkpoint inhibitors. It is also preparing to initiate a single randomized placebo-controlled which is in Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda; and Delta receptor technology to develop tumor microenvironment modulators in the form of first-in-class bi-functional and bi-specific antibody-drug conjugates targeting Myeloid Derived Suppressor Cells. In addition, the company is also developing Immune Fx; IFx-3.0, an mRNA innate immune agonist candidate for intravenous or autologous whole cell administration for blood-related cancers. The company was formerly known as Morphogenesis, Inc. and changed its name to TuHURA Biosciences, Inc. in December 2023. The company was founded in 1995 and is based in Tampa, Florida. TuHURA Biosciences, Inc. operates as a subsidiary of CohBar, Inc.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $0M | $-29M | $-30M | $-28M | -143.6% | - | - |
| 2024 | $0M | $-17M | $-22M | $-15M | -148.6% | - | - |
| 2023 | $0M | $-29M | $-29M | $-12M | 1880.8% | - | - |
| 2022 | $0M | $-9M | $-9M | $-8M | -76.1% | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total Revenue | 0 | 0 | 0 | 0 |
| Operating Expense | 9.72 | 13.17 | 17.15 | 27.29 |
| Operating Income | -9.72 | -13.17 | -17.15 | -27.29 |
| EBITDA | -8.99 | -29.12 | -17.43 | -29.36 |
| EBIT | -9.37 | -29.30 | -17.54 | -29.43 |
| Pretax Income | -9.37 | -29.32 | -21.68 | -30.05 |
| Net Income | -9.37 | -29.32 | -21.68 | -30.05 |
| Net Income Common Stockholders | -9.37 | -29.32 | -22.65 | -30.06 |
| Total Expenses | 9.72 | 13.17 | 17.15 | 27.29 |
| Interest Expense | 0 | 0.02 | 4.14 | 0.63 |
| Interest Income | 0.06 | 0.09 | 0.36 | 0.14 |
| Research And Development | 7.93 | 9.40 | 13.34 | 20.53 |
| Selling General And Administration | 2.01 | 4.14 | 3.87 | 7.58 |
| Normalized EBITDA | -9.29 | -12.90 | -16.67 | -27.08 |
| Normalized Income | -9.66 | -13.10 | -20.93 | -27.78 |
| Basic EPS | -0.77 | -2.47 | -1.21 | -0.63 |
| Diluted EPS | -0.77 | -2.47 | -1.21 | -0.63 |
| Tax Effect Of Unusual Items | 0 | 0 | 0 | 0 |
| Tax Rate For Calcs | 0 | 0 | 0 | 0 |
| Total Unusual Items | 0.29 | -16.22 | -0.75 | -2.27 |
| Total Unusual Items Excluding Goodwill | 0.29 | -16.22 | -0.75 | -2.27 |
| Net Income From Continuing Operation Net Minority Interest | -9.37 | -29.32 | -21.68 | -30.05 |
| Reconciled Depreciation | 0.37 | 0.18 | 0.12 | 0.07 |
| Net Interest Income | 0.06 | 0.07 | -3.78 | -0.49 |
| Net Income From Continuing And Discontinued Operation | -9.37 | -29.32 | -21.68 | -30.05 |
| Total Operating Income As Reported | -9.93 | -29.76 | -17.65 | -31.80 |
| Diluted Average Shares | 12.18 | 11.89 | 18.66 | 47.93 |
| Basic Average Shares | 12.18 | 11.89 | 18.66 | 47.93 |
| Diluted NI Availto Com Stockholders | -9.37 | -29.32 | -22.65 | -30.06 |
| Otherunder Preferred Stock Dividend | 0 | 0 | 0.97 | 0 |
| Preferred Stock Dividends | 0 | 0 | 0 | 0.01 |
| Net Income Including Noncontrolling Interests | -9.37 | -29.32 | -21.68 | -30.05 |
| Net Income Continuous Operations | -9.37 | -29.32 | -21.68 | -30.05 |
| Other Income Expense | 0.29 | -16.22 | -0.75 | -2.27 |
| Special Income Charges | 0.29 | -16.22 | -0.44 | -3.86 |
| Other Special Charges | -0.29 | 16.22 | 0.44 | 3.68 |
| Write Off | 0 | 0 | 0 | 0 |
| Restructuring And Mergern Acquisition | 0 | 0 | 0 | 0.19 |
| Gain On Sale Of Security | 0 | 0 | -0.31 | 1.59 |
| Net Non Operating Interest Income Expense | 0.06 | 0.07 | -3.78 | -0.49 |
| Interest Expense Non Operating | 0 | 0.02 | 4.14 | 0.63 |
| Interest Income Non Operating | 0.06 | 0.09 | 0.36 | 0.14 |
| Other Operating Expenses | -0.21 | -0.04 | -0.06 | -0.71 |
| Other Taxes | 0 | -0.33 | 0 | -0.11 |
| General And Administrative Expense | 2.01 | 4.14 | 3.87 | 7.58 |
| Other Gand A | 2.01 | 4.14 | 3.87 | 7.58 |
| Operating Revenue | 0 | 0 | 0 | 0 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| TuHURA Biosciences, Inc.this co. | HURA | $134M | - | 6.03 | -143.6% | -4.67 |
| Fate Therapeutics, Inc. | FATE | $144M | - | 0.69 | -65.8% | -0.14 |
| Quanterix Corporation | QTRX | $144M | - | 0.48 | -36.2% | -0.86 |
| SANUWAVE Health, Inc. | SNWV | $143M | 40.51 | 88.35 | 729.6% | 20.54 |
| AVITA Medical, Inc. | RCEL | $130M |
| - |
| -7.76 |
| 291.8% |
| -3.91 |
| The Joint Corp. | JYNT | $127M | - | 8.33 | 19.3% | 140.09 |
| Nano-X Imaging Ltd. | NNOX | $119M | - | 0.85 | -28.3% | -1.41 |
| Neuronetics, Inc. | STIM | $118M | - | 5.25 | -148.6% | -6.65 |
| OptimizeRx Corporation | OPRX | $115M | 22.74 | 0.90 | 4.0% | 7.20 |
| Peer Median | - | 31.63 | 0.87 | -12.1% | -0.50 | |